Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma

NIH RePORTER · NIH · U19 · $199,833 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY: IDEAL Administrative Core Our overall proposal will investigate immune development in early life (IDEAL) to identify IDEAL endotypes that correspond to key clinical outcomes in childhood, including vaccine response, respiratory infectious disease and asthma. We will accomplish this goal through three distinct yet integrated studies that follow complementary approaches via cutting-edge in silico (project 1, PR1), epigenetic (PR2), and in vitro (PR3) research projects. Given the scientific scope, complexity, and geographic range of the proposed work, the study IDEAL Administrative Core (AC) will be crucial to optimize the quality and impact of the proposed studies and to ensure timely provision of projected deliverables. The goal of the IDEAL-AC is to institute streamlined processes which facilitate productive interactions among investigators from each IDEAL Project and Core. We will achieve this goal by pursuing the following Specific Aims (SAs): SA1. Provide infrastructure for administrative leadership aimed at building an interactive and collaborative working team resulting in maximal project synergy. SA2. Facilitate and promote communication and interactions amongst the Project and Core Leads by conducting regular teleconferences/face-to-face meetings, annual meetings, as well as seminars/symposia focused on the IDEAL project. SA3. Manage and optimize communication within our IDEAL team and between our team, the other NIH supported IDEAL teams and the IDEAL Steering Committee. SA4. Resolve potential conflicts that might arise within and outside of our IDEAL project by implementing recommendations of the Conflicts Resolution Group (CRG). SA5. Provide fiscal, regulatory and scientific oversight, review and consolidate yearly progress reports sent to the NIH. SA6. Protect intellectual property rights of our investigators and execute material transfer agreements. SA7. Implement the data management/sharing plan among investigators within and outside of our IDEAL team. Overall, the IDEAL AC will ensure appropriate stewardship of NIH funds and maintain adherence to project timelines, all with the goal to optimize and amplify the scientific impact of the proposed studies.

Key facts

NIH application ID
10796876
Project number
5U19AI168643-03
Recipient
BOSTON CHILDREN'S HOSPITAL
Principal Investigator
OFER LEVY
Activity code
U19
Funding institute
NIH
Fiscal year
2024
Award amount
$199,833
Award type
5
Project period
2022-03-10 → 2027-02-28